GSK plc — 6-K Filings
6,008 6-K filings on record
This page lists all 6-K filings submitted to the SEC by GSK plc (GLAXF), sorted by most recent first. Each row links to the full filing on EdgarLookup. GSK plc has filed 6,008 6-K documents with the SEC since 2021. To view all SEC filings by GSK plc, see the full filings list.
All
11-K
13F-HR
20-F
20-F/A
25-NSE
3
3/A
4
4/A
424B2
424B3
5
6-K
6-K/A
8-A12B
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3/A
F-3ASR
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
POS AM
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G/A
SD
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001411 | Feb 20, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001425 | Feb 20, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001380 | Feb 19, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001372 | Feb 19, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001330 | Feb 18, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001267 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001265 | Feb 17, 2026 | — |
| 6-K | GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME | 0001654954-26-001288 | Feb 17, 2026 | — |
| 6-K | EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | 0001654954-26-001276 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001295 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001297 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001262 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001125 | Feb 11, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001116 | Feb 11, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001123 | Feb 11, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001113 | Feb 11, 2026 | — |
| 6-K | CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION | 0001654954-26-001068 | Feb 10, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001035 | Feb 9, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000976 | Feb 6, 2026 | — |
| 6-K | NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION | 0001654954-26-000970 | Feb 6, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000949 | Feb 5, 2026 | — |
| 6-K | FINAL RESULTS | 0001654954-26-000892 | Feb 4, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000829 | Feb 2, 2026 | — |
| 6-K | EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ | 0001654954-26-000581 | Jan 26, 2026 | — |
| 6-K | AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING | 0001654954-26-000468 | Jan 20, 2026 | — |
| 6-K | GSK TO ACQUIRE RAPT THERAPEUTICS | 0001654954-26-000470 | Jan 20, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000417 | Jan 16, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000375 | Jan 15, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000324 | Jan 13, 2026 | — |
| 6-K | EC APPROVAL OF SHINGRIX PFS | 0001654954-26-000138 | Jan 7, 2026 | — |
| 6-K | POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN | 0001654954-26-000136 | Jan 7, 2026 | — |
| 6-K | EXDENSUR APPROVED IN JAPAN | 0001654954-26-000107 | Jan 6, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000071 | Jan 5, 2026 | — |
| 6-K | NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA | 0001654954-26-000056 | Jan 5, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000061 | Jan 5, 2026 | — |
| 6-K | GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US | 0001654954-25-014268 | Dec 23, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014212 | Dec 22, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014156 | Dec 22, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014129 | Dec 19, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014074 | Dec 18, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014027 | Dec 17, 2025 | — |
| 6-K | EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA | 0001654954-25-014033 | Dec 17, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013979 | Dec 16, 2025 | — |
| 6-K | EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL | 0001654954-25-013981 | Dec 16, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013922 | Dec 15, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013879 | Dec 12, 2025 | — |
| 6-K | POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ | 0001654954-25-013882 | Dec 12, 2025 | — |
| 6-K | NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD | 0001654954-25-013887 | Dec 12, 2025 | — |
| 6-K | DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION | 0001654954-25-013890 | Dec 12, 2025 | — |
| 6-K | BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION | 0001654954-25-013845 | Dec 11, 2025 | — |